Fri, October 4, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. SMMT
Healthcare
Facebook Twitter Linkedin

Summit Therapeutics PLC (NASDAQ:SMMT)

18.46 USD

-1.080 5.527%
Last Updated at: 2024-10-03T18:52:00Z

Summit Therapeutics PLC

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

601 Brickell Key Drive, Miami, FL, United States, 33131

650 460 8308

https://www.summittxinc.com

Employees: 105

Key Executives

Sr. No. Name Title Year Born
1. Mr. Robert W. Duggan CEO & Exec. Chairman 1944
2. Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA Co-CEO, Pres & Director 1970
3. Dr. Urte Gayko Ph.D. Head of Regulatory Affairs, Quality Assurance & Safety and Director 1971
4. Prof. Dame Kay Davies DBE, FRS CBE Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor 1951
5. Mr. Ankur Dhingra Chief Financial Officer 1976
6. Ms. Michelle Avery Director of Investor Relations NA
7. Dr. Elaine Carla Stracker J.D., Ph.D. Head of Compliance? & Gen. Counsel 1961
8. Mr. Campbell Hair Head of HR? NA
9. Dr. Anne Heatherington Head of Clinical Devel. and Quantitative Sciences NA
10. Ms. Divya Chari Head of Global Clinical Operations 1968

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.940 0.807% 116.24 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 0.000 0.000% 116.2 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 -9.265 2.005% 460 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 -24.030 2.310% 1037.5 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 31-01-2023 31-01-2022 31-01-2021 31-01-2020 31-01-2019
Income Before Tax -78.782M -88.602M -52.91M 4.994M 6.598M
Minority Interest - - - - 0M
Net Income -74.381M -86.147M -52.697M 4.994M 9.872M
Selling General Administrative 26.7M 23.611M 19.232M - 16.187M
Gross Profit 0.704M 1.809M 0.86M 43.012M 56.388M
Reconciled Depreciation 2.514M 2.455M 2.003M - 1.493M
Ebit -72.089M -88.641M -53.193M -25.556M 12.381M
Ebitda -60.803M -86.186M -51.475M 15.156M 13.874M
Depreciation And Amortization 11.286M 2.455M 1.718M 0.524M 1.493M
Operating Income -72.089M -86.186M -53.193M 15.156M 12.381M
Other Operating Expenses 64.283M 87.995M 53.194M -39.182M 47.688M
Interest Expense 4.401M 0.281M 0.255M 0M 0.556M
Tax Provision - 0M -0.213M - -3.274M
Interest Income - 0M 0.004M - 0.005M
Net Interest Income -4.401M -0.281M -0.251M - 3.101M
Income Tax Expense -4.401M -2.455M -0.213M -3.844M -3.274M
Total Revenue 0.704M 1.809M 0.86M 43.012M 56.413M
Total Operating Expenses 64.283M 87.995M 53.194M -39.182M 47.688M
Cost Of Revenue - - - - 0.025M
Total Other Income Expense Net -6.693M -2.416M 0.283M -10.162M -5.783M
Net Income From Continuing Ops -78.782M -88.602M -52.697M - 9.872M
Net Income Applicable To Common Shares -78.782M -88.602M -52.697M -24.035M 7.527M

Balance Sheet

(Currency in USD)
Breakdown 31-01-2024 31-01-2023 31-01-2022 31-01-2021 31-01-2020
Total Assets 202.949M 664.168M 113.374M 102.498M 24.439M
Intangible Assets - - 10.399M 11.515M 10.604M
Other Current Assets 0.181M 0.486M 1.201M 1.523M 5.8M
Total Liab 125.257M 537.514M 30.09M 23.045M -18.098M
Total Stockholder Equity 77.692M 126.654M 83.284M 79.453M 42.537M
Other Current Liab 0.717M 16.967M 12.219M 4.99M 1.494M
Common Stock 7.017M 2.11M 0.98M 0.826M 3.359M
Capital Stock 7.017M 2.11M 0.98M 0.826M -
Retained Earnings -993.258M -378.33M -299.548M -214.74M -97.619M
Good Will 1.893M 1.798M 2.009M 2.03M 1.814M
Other Assets - 0.577M 25.521M - -16.377M
Cash 71.425M 348.607M 71.791M 66.417M 26.858M
Cash And Equivalents - - - - -
Total Current Liabilities 20.405M 38.782M 25.623M 19.89M -1.836M
Current Deferred Revenue 14.212M - 7.939M 8.37M -0.831M
Net Debt 34.674M 170.156M -69.009M -65.952M -27.863M
Short Term Debt 2.809M 21.46M 1.091M 0.39M -1.005M
Short Long Term Debt - 19.77M - - -
Short Long Term Debt Total 106.099M 518.763M 2.782M 0.465M -1.005M
Other Stockholder Equity 1066.381M 504.767M 384.049M 293.367M 42.537M
Property Plant Equipment - 5.081M 3.484M 1.279M 1.167M
Total Current Assets 189.712M 656.712M 97.312M 66.417M 26.858M
Long Term Investments - - - - -
Short Term Investments 114.817M - - - -
Net Receivables 0.848M 6.115M 17.159M 10.187M 5.13M
Long Term Debt 100M 494.54M - - -
Inventory 2.441M 301.504M 7.161M -11.71M -
Accounts Payable 2.667M 0.355M 4.374M 6.14M 3.389M
Accumulated Other Comprehensive Income -2.448M -1.893M -2.197M -3.794M -
Non Currrent Assets Other 5.281M 0.577M 0.17M 21.257M -
Non Current Assets Total 13.237M 7.456M 16.062M 36.081M 13.958M
Capital Lease Obligations 6.099M 4.453M 2.782M 0.465M -
Long Term Debt Total - - - - -

Cash Flow

(Currency in USD)
Breakdown 31-01-2023 31-01-2022 31-01-2021 31-01-2020 31-01-2019
Investments -0.624M -0.306M -0.421M - -0.411M
Total Cashflows From Investing Activities -0.624M -0.306M -0.421M -0.287M -0.313M
Total Cash From Financing Activities 620.244M 77.916M 50.551M 33.113M 43.855M
Net Income -78.782M -88.602M -52.697M -25.556M 6.598M
Change In Cash 576.816M 5.374M 2.575M 6.756M 8.861M
Begin Period Cash Flow 71.791M 66.417M 63.842M 20.102M 26.365M
End Period Cash Flow 648.607M 71.791M 66.417M 26.858M 35.226M
Total Cash From Operating Activities -41.582M -72.587M -48.111M -26.663M -35.143M
Depreciation 2.514M 2.455M 2.003M 1.473M 1.493M
Other Cashflows From Investing Activities - - -0.421M 0.004M 0.004M
Dividends Paid - - - - 0M
Change To Inventory - 3.595M -6.607M - 0M
Sale Purchase Of Stock - - - - 0M
Other Cashflows From Financing Activities 545.244M 112.916M 0.551M 33.113M -1.588M
Capital Expenditures 0.624M 0.306M 0.421M 0.119M 0.164M
Change In Working Capital 8.616M -0.067M 0.619M 4.375M -51.181M
Other Non Cash Items 14.122M 0.497M -0.385M -28.136M 1.726M
Free Cash Flow -42.206M -72.893M -48.532M -26.782M -35.307M

Funds

Sr. No. Name Purchased On Shares
1. SPDR® S&P Biotech ETF 5 months ago 5048900
2. Fidelity Select Biotechnology 6 months ago 4354329
3. Vanguard Total Stock Mkt Idx Inv 5 months ago 3591598
4. iShares Russell 2000 ETF 5 months ago 2690215
5. Vanguard Institutional Extnd Mkt Idx Tr 5 months ago 1882444
6. Fidelity Small Cap Index 7 months ago 1185193
7. Fidelity Select Health Care 6 months ago 1000000
8. iShares Russell 2000 Growth ETF 5 months ago 975789
9. Fidelity Extended Market Index 6 months ago 719642
10. State St Russell Sm/Mid Cp® Indx NL Cl C 5 months ago 713485
11. Fidelity Growth Compy Commingled Pl O 6 months ago 691500
12. iShares Biotechnology ETF 5 months ago 605784
13. Fidelity Advisor Health Care I 6 months ago 600000
14. Schwab US Small-Cap ETF™ 5 months ago 595901
15. Fidelity Growth Company Fund 6 months ago 526499
16. Direxion Daily S&P Biotech Bull 3X ETF 5 months ago 508069
17. ALPS Medical Breakthroughs ETF 5 months ago 491087
18. Vanguard Health Care ETF 5 months ago 472726
19. Vanguard Russell 2000 ETF 5 months ago 432710
20. State St Russell Sm Cap® Indx SL Cl I 5 months ago 422700

Institutions

Sr. No. Name Purchased On Shares
1. BlackRock Inc 9 months ago 9759383
2. Vanguard Group Inc 6 months ago 7269243
3. Geode Capital Management, LLC 9 months ago 3085666
4. State Street Corporation 9 months ago 2456168
5. Northern Trust Corp 9 months ago 1108089
6. Charles Schwab Investment Management Inc 6 months ago 1016545
7. Morgan Stanley - Brokerage Accounts 9 months ago 704272
8. Rafferty Asset Management, LLC 6 months ago 650286
9. Steward Partners Investment Advisory, LLC 9 months ago 600000
10. Nuveen Asset Management, LLC 9 months ago 565624
11. Citigroup Inc 6 months ago 559006
12. Federated Hermes Inc 6 months ago 551769
13. ALPS Advisors Inc 6 months ago 494924
14. Goldman Sachs Group Inc 9 months ago 388816
15. Bank of New York Mellon Corp 9 months ago 342529
16. Barclays PLC 9 months ago 318565
17. Sectoral Asset Management Inc 6 months ago 315000
18. JPMorgan Chase & Co 9 months ago 296205
19. Swiss National Bank 6 months ago 275000
20. Susquehanna International Group, LLP 9 months ago 230350
Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App